Switch theme
Sign up to access all valuation multiples
Sino Biological Inc is an international reagent supplier and service provider. The company specializes in recombinant protein production and antibody development. All of Sino Biological's products are independently developed and produced, including recombinant proteins, antibodies and cDNA clones.
2016
n/a
LTM Revenue $87.7M
LTM EBITDA $57.8M
$522M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Sino Biological has a last 12-month revenue (LTM) of $87.7M and a last 12-month EBITDA of $57.8M.
In the most recent fiscal year, Sino Biological achieved revenue of $85.2M and an EBITDA of $32.8M.
Sino Biological expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Sino Biological valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $87.7M | XXX | $85.2M | XXX | XXX | XXX |
| Gross Profit | $64.0M | XXX | $62.4M | XXX | XXX | XXX |
| Gross Margin | 73% | XXX | 73% | XXX | XXX | XXX |
| EBITDA | $57.8M | XXX | $32.8M | XXX | XXX | XXX |
| EBITDA Margin | 66% | XXX | 39% | XXX | XXX | XXX |
| EBIT | $20.9M | XXX | $7.6M | XXX | XXX | XXX |
| EBIT Margin | 24% | XXX | 9% | XXX | XXX | XXX |
| Net Profit | $18.0M | XXX | $16.9M | XXX | XXX | XXX |
| Net Margin | 20% | XXX | 20% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Sino Biological's stock price is CNY 63 (or $9).
Sino Biological has current market cap of CNY 7.7B (or $1.1B), and EV of CNY 3.8B (or $522M).
See Sino Biological trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $522M | $1.1B | XXX | XXX | XXX | XXX | $0.15 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Sino Biological has market cap of $1.1B and EV of $522M.
Sino Biological's trades at 6.1x EV/Revenue multiple, and 15.9x EV/EBITDA.
Equity research analysts estimate Sino Biological's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Sino Biological has a P/E ratio of 59.1x.
See valuation multiples for Sino Biological and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $522M | XXX | $522M | XXX | XXX | XXX |
| EV/Revenue | 5.9x | XXX | 6.1x | XXX | XXX | XXX |
| EV/EBITDA | 9.0x | XXX | 15.9x | XXX | XXX | XXX |
| EV/EBIT | 24.9x | XXX | 68.7x | XXX | XXX | XXX |
| EV/Gross Profit | 8.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 59.1x | XXX | 62.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 85.9x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSino Biological's last 12 month revenue growth is 10%
Sino Biological's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Sino Biological's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Sino Biological's rule of X is 91% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Sino Biological and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 10% | XXX | 11% | XXX | XXX | XXX |
| EBITDA Margin | 66% | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | -29% | XXX | -13% | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 49% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 91% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 15% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 64% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Jubilant Pharmova | XXX | XXX | XXX | XXX | XXX | XXX |
| Biocon | XXX | XXX | XXX | XXX | XXX | XXX |
| Syngene International | XXX | XXX | XXX | XXX | XXX | XXX |
| Dishman Carbogen Amics | XXX | XXX | XXX | XXX | XXX | XXX |
| Cohance Lifesciences | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Sino Biological acquired XXX companies to date.
Last acquisition by Sino Biological was XXXXXXXX, XXXXX XXXXX XXXXXX . Sino Biological acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Sino Biological founded? | Sino Biological was founded in 2016. |
| Where is Sino Biological headquartered? | Sino Biological is headquartered in China. |
| Is Sino Biological publicy listed? | Yes, Sino Biological is a public company listed on SHE. |
| What is the stock symbol of Sino Biological? | Sino Biological trades under 301047 ticker. |
| When did Sino Biological go public? | Sino Biological went public in 2021. |
| Who are competitors of Sino Biological? | Similar companies to Sino Biological include e.g. Jubilant Pharmova, Biocon, Syngene International, Dishman Carbogen Amics. |
| What is the current market cap of Sino Biological? | Sino Biological's current market cap is $1.1B |
| What is the current revenue of Sino Biological? | Sino Biological's last 12 months revenue is $87.7M. |
| What is the current revenue growth of Sino Biological? | Sino Biological revenue growth (NTM/LTM) is 10%. |
| What is the current EV/Revenue multiple of Sino Biological? | Current revenue multiple of Sino Biological is 5.9x. |
| Is Sino Biological profitable? | Yes, Sino Biological is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Sino Biological? | Sino Biological's last 12 months EBITDA is $57.8M. |
| What is Sino Biological's EBITDA margin? | Sino Biological's last 12 months EBITDA margin is 66%. |
| What is the current EV/EBITDA multiple of Sino Biological? | Current EBITDA multiple of Sino Biological is 9.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
